Who are Flublok™ Quadrivalent by Sanofi, Inc.'s main competitors?

No direct comparators detected in our index.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/flublok-quadrivalent-by-sanofi-inc.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Flublok™ Quadrivalent by Sanofi, Inc. — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Flublok™ Quadrivalent by Sanofi, Inc. (Flublok™ Quadrivalent by Sanofi, Inc.) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Recombinant inactivated influenza vaccine. Area: Immunology / Infectious Disease.

marketed Recombinant inactivated influenza vaccine Influenza hemagglutinin (HA) protein Immunology / Infectious Disease Biologic Live · refreshed every 30 min

Target snapshot

Flublok™ Quadrivalent by Sanofi, Inc. (Flublok™ Quadrivalent by Sanofi, Inc.) — Centers for Disease Control and Prevention. Flublok Quadrivalent is an inactivated influenza vaccine produced using recombinant DNA technology that stimulates the immune system to produce antibodies against four strains of influenza virus.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Flublok™ Quadrivalent by Sanofi, Inc. TARGET	Flublok™ Quadrivalent by Sanofi, Inc.	Centers for Disease Control and Prevention	marketed	Recombinant inactivated influenza vaccine	Influenza hemagglutinin (HA) protein

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Recombinant inactivated influenza vaccine class)

Centers for Disease Control and Prevention · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Flublok™ Quadrivalent by Sanofi, Inc. — Competitive Intelligence Brief. https://druglandscape.com/ci/flublok-quadrivalent-by-sanofi-inc. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab